Drug intelligence / Profile preview

IMNN-102

Development stage: Preclinical
Lead developer: IMUNON
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular (inferred Based On Typical Administration Route For Dna Vaccines)

Overview

IMNN-102 is a DNA-based vaccine being developed by Imunon using its proprietary PlaCCine platform for the prevention of Lassa virus fever. The PlaCCine platform utilizes synthetic DNA plasmids encoding pathogen antigens, delivered via a non-viral system to induce an immune response against the target pathogen. IMNN-102 is currently in preclinical development as a prophylactic vaccine candidate specifically targeting Lassa virus, which causes Lassa fever, a severe viral hemorrhagic illness endemic in parts of West Africa[1][4][9].

Targets

GPC (Lassa virus glycoprotein complex)

Beyond the preview

Go deeper on IMNN-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMNN-102.

Explore the full profile